Puma Biotechnology (PBYI) Other Non-Current Liabilities (2020 - 2024)

Puma Biotechnology has reported Other Non-Current Liabilities for 5 years, with the latest figure at $121000.0 in Q4 2024.

• For the quarter ending Q4 2024, Other Non-Current Liabilities changed 0.0% year-over-year to $121000.0; the trailing twelve-month figure through Dec 2024 stood at $121000.0 (changed 0.0% YoY), and the FY2024 full-year result was $121000.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities for Q4 2024 stood at $121000.0, roughly flat from $121000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $26.0 million in Q4 2020, with the low at $37000.0 in Q3 2020.
• Historically, Other Non-Current Liabilities has averaged $3.4 million across 5 years, with a median of $121000.0 in 2023.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities sank 99.86% — and 2023, when it soared 20816.22%.
• Puma Biotechnology's Other Non-Current Liabilities stood at $26.0 million in 2020, then slumped by 99.86% to $37000.0 in 2021, then surged by 19875.68% to $7.4 million in 2022, then plunged by 98.36% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024.
• The last three Other Non-Current Liabilities figures came in at $121000.0 (Q4 2024), $121000.0 (Q3 2024), and $121000.0 (Q2 2024), per Business Quant data.